ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
09 Octobre 2023 - 2:30PM
via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC)
("Company"), a clinical-stage biopharmaceutical company developing
therapeutic solutions in ophthalmology, neurology, and
oncology/hematology, announced today that it received a Taiwanese
patent, Application No. 109130285, for the use of PDC-1421, a Radix
Polygala (Polygala tenuifolia Willd) extract, which is used in the
Company’s asset ABV-1504 for the treatment of Major Depressive
Disorder (MDD). The Company was previously awarded a U.S. patent,
US 11,554,154 B2, on April 25, 2023, for the same treatment.
"These patents grant ABVC the right to exclude others from
using, offering, or selling PDC-1421, throughout the United States
and Taiwan until the year of 2040," said Dr. Uttam Patil, ABVC
Chief Executive Officer. "As our patent map steps into global
coverage, we eagerly await the results of patent applications in
the European Union, China, Japan, and more."
The patent application was submitted to the Taiwan Patent and
Trademark Office under the title "Polygala Extract for the
Treatment of Major Depressive Disorder." The invention relates to
oral administration of the formulation containing a Radix Polygala
(Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for
treating Major Depressive Disorder. Based on current studies,
administering the composition should be done over the course of at
least 25 days, with the daily dose varying once, twice, or three
times per day; each dose ranges between 380-760 mg of the botanical
extraction.
ABV-1504, the Company’s asset indicated for use in MDD
containing PDC-1421, is a botanical-based Norepinephrine
Transporter (NET) inhibitor that has completed Phase II clinical
studies, with plans to initiate an End of Phase II (EOP II) meeting
with the FDA.
We believe the Company's pipeline products have great market
potential. As per the Future Market Insights report, the MDD market
was valued at $11.51 billion in 2022 and is expected to reach
$14.96 billion by 2032 with a CAGR of 2.8% over the forecast
period.1 According to the Polaris market research report, the
global ADHD treatment market was valued at $16.13 billion in 2022
and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1%
over the forecast period.2
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company
with an active pipeline of six drugs and one medical device
(ABV-1701/Vitargus®) under development. For its drug products, the
Company utilizes in-licensed technology from its network of
world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company's
network of research institutions includes Stanford University,
University of California at San Francisco, and Cedars-Sinai Medical
Center. For Vitargus®, the Company intends to conduct global
clinical trials through Phase III.
Forward-Looking Statements
This press release contains "forward-looking statements." Such
statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential," or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
None of the outcomes expressed herein are guaranteed. Such risks
and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to proceed to the next level of the clinical
trials or to market our product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission
(SEC), including the Company's Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors are urged to read these
documents free of charge on the SEC's website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy any of the Company's securities,
nor shall such securities be offered or sold in the United States
absent registration or an applicable exemption from registration,
nor shall there be any offer, solicitation or sale of any of the
Company's securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such state or
jurisdiction.
Contact:
Tom MastersonEmail: tmasterson@allelecomms.com
[1]
https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%...
[2]
https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market...
ABVC BioPharma (NASDAQ:ABVC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ABVC BioPharma (NASDAQ:ABVC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024